PureTech Health has long occupied an unusual corner of the London market: a biotechnology group that behaves less like a single drug developer and more like an assembly line for new companies. Its 'hub-and-spoke' approach has already produced one of the sector's landmark exits, and 2026 has brought a flurry of activity — a Nasdaq flotation for one offshoot, a fresh $180m financing for another, and the company's own decision to consolidate its share quotation in London.

The Quick Version

  • PureTech ended its Nasdaq ADS listing in May 2026 and now trades primarily on the London Main Market under PRTC, with ADSs quoted over-the-counter.
  • Lead candidate deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis has moved into Founded Entity Celea Therapeutics, which raised $180m in July 2026; PureTech holds a 35.4% fully diluted stake.
  • The group reported consolidated cash and short-term investments of $277.3m at 31 December 2025 and guided to an operational runway at least through end-2028.
  • PureTech retains a Cobenfy royalty following the $14bn Karuna/Bristol Myers Squibb deal, plus stakes in Nasdaq-listed Seaport Therapeutics and oncology venture Gallop.
  • The story hinges on execution across multiple part-owned companies, and on whether monetisation events narrow any gap between market value and portfolio worth.

The Hub-and-Spoke Model

PureTech identifies scientific advances, builds development programmes around them, and either advances them in-house or seeds them into separately capitalised 'Founded Entities.' The signature success remains Karuna Therapeutics — Bristol Myers Squibb completed its $14bn acquisition of Karuna in March 2024, and the underlying medicine, Cobenfy, secured FDA clearance on 26 September 2024 as the first novel schizophrenia mechanism approved in decades.

A notable feature of 2025-2026 has been the migration of PureTech's most advanced in-house assets into this Founded Entity structure — complicating the traditional picture of a lead asset advancing under one corporate roof.

The Nasdaq Delisting

In May 2026, PureTech voluntarily delisted its ADSs from Nasdaq (Form 25 filed around 11 May 2026), with the board's stated rationale being that the substantial majority of trading volume, liquidity and price discovery already occurred in London. The ADSs now trade over-the-counter through a sponsored Level 1 programme; the London Main Market listing under PRTC is unaffected and remains primary.

Two Spin-Outs in Quick Succession

On 1 May 2026, Founded Entity Seaport Therapeutics (built around a 'Glyph' bioavailability platform for neuropsychiatric medicines) priced its Nasdaq IPO under SPTX, raising $254.9m gross at $18.00 a share. PureTech was expected to hold 16,685,013 Seaport shares — a position valued at roughly $300m at the IPO price.

Then, on 2 July 2026, PureTech placed deupirfenidone (LYT-100), its most advanced respiratory asset for idiopathic pulmonary fibrosis, into newly launched Celea Therapeutics, which completed a $180m financing with RA Capital Management and Leaps by Bayer among investors. PureTech reported a 35.4% fully diluted stake, having invested $30m with a further $70m earmarked, retaining tiered royalties of 1-3% on net sales, up to $190m in milestones, and 20% of sublicense income.

The Cobenfy Royalty

PureTech sold the royalty stream on annual Cobenfy net sales up to $2bn to Royalty Pharma for consideration up to $500m, while retaining a 2% royalty on annual net sales above that threshold, shared 67/33 with Royalty Pharma, plus rights to certain regulatory milestone payments — a hybrid structure securing near-term cash while preserving upside should Cobenfy become a large commercial franchise.

The Financial Position

Consolidated cash, cash equivalents and short-term investments were $277.3m at 31 December 2025, with PureTech-level cash of $248.1m at 31 March 2026. Management guided to an operational runway at least through end-2028 — a comparatively comfortable horizon reflecting capital returned from the Karuna exit. PureTech completed a $100m tender offer in June 2024, repurchasing roughly 12% of issued capital at 250p per share.

Why the Complexity Is the Whole Point — and the Risk

A recurring theme in commentary on holding-company structures is that portfolios like this can trade at a discount to the sum of their parts, reflecting the difficulty of valuing private stakes and uncertainty over future dilution. PureTech's economic interest in each asset is fractional and indirect — a blockbuster outcome for any one asset benefits the group only in proportion to its retained interest, which can shrink as the relevant company raises further capital.

Risks Worth Weighing

Clinical failure is ever-present — a Phase 3 IPF trial is expensive and far from assured. Because value is distributed across part-owned entities, PureTech's economic interest can be diluted by future financings, and it doesn't control the strategy of Seaport or the commercialisation of Cobenfy by BMS. Several former holdings sit in a 'Legacy Holdings' category with no current capital-allocation focus. The structural complexity itself demands unusual diligence and can deter generalist capital.

What to Watch Next

Initiation of the Phase 3 SURPASS-IPF trial for deupirfenidone, planned for early Q3 2026. Final overall-survival data from Gallop's LYT-200 Phase 1b programme in AML and MDS, expected H1 2026. Progress at Seaport, including data from its lead depression programme. Any additional Cobenfy royalty milestones or further Founded Entity financings.